Get the Stockscreener App
7.6306
0.81%
-0.0594
Aura Biosciences Inc stock is traded at $7.6306, with a volume of 3.42M.
It is down -0.81% in the last 24 hours and up +9.12% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$7.69
Open:
$7.71
24h Volume:
3.42M
Relative Volume:
5.66
Market Cap:
$793.86M
Revenue:
-
Net Income/Loss:
$-112.39M
P/E Ratio:
-4.3275
EPS:
-1.7633
Net Cash Flow:
$-91.64M
1W Performance:
-0.94%
1M Performance:
+9.12%
6M Performance:
+45.28%
1Y Performance:
+13.50%
1-Day Range:
$7.55
$7.82
1-Week Range:
$7.07
$8.20
52-Week Range:
$4.73
$9.535
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
7.655 | 797.49M | 0 | -112.39M | -91.64M | -1.7633 |
VRTX
Vertex Pharmaceuticals Inc
|
515.63 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.01 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.71 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.05 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.46 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Resumed | Evercore ISI | Outperform |
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
View All
Aura Biosciences Inc Stock (AURA) Latest News
Wall Street Zen Downgrades Aura Biosciences (NASDAQ:AURA) to Sell - marketbeat.com
Frazier funds disclose Aura Biosciences (AURA) stake and 9.99% warrant cap - Stock Titan
Aura Biosciences (AURA): Long Focus Capital reports 4.9% ownership - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
HC Wainwright Raises Earnings Estimates for Aura Biosciences - MarketBeat
LifeSci Capital Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $23 - Moomoo
Aura Biosciences (AURA) files Form 3 for Chief People Officer Julie Person - Stock Titan
Aura Biosciences (AURA) officer Erica Kratz files initial Form 3 insider report - Stock Titan
Aura Biosciences (AURA) COO Susan Abu-Absi files initial insider Form 3 - Stock Titan
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval - Seeking Alpha
AURA BIOSCIENCES, INC. : H.C. WAINWRIGHT CUTS TARGET PRICE TO $18 FROM $24 - webull.com
Aura refocuses clinical plans, reduces staff by 20% - The Business Journals
H.C. Wainwright Maintains Aura Biosciences(AURA.US) With Buy Rating, Maintains Target Price $18 - Moomoo
Adage Capital discloses 9.1M Aura Biosciences (AURA) shares under shared control - Stock Titan
Aura Biosciences (NASDAQ:AURA) Shares Gap Down on Disappointing Earnings - marketbeat.com
H.C. Wainwright cuts Aura Biosciences stock price target on strategic shift - Investing.com Nigeria
Analysts Offer Predictions for AURA Q1 Earnings - marketbeat.com
Aura BiosciencesMay Offer Securities Up To $500 Million Aggregate - TradingView
Aura Biosciences (NASDAQ: AURA) sets $500M shelf and $200M ATM - stocktitan.net
Aura Biosciences Releases Q2 2026 Financial Results - AlphaStreet
HC Wainwright Lowers Aura Biosciences (NASDAQ:AURA) Price Target to $18.00 - MarketBeat
Aura Biosciences (NASDAQ:AURA) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS - marketbeat.com
Aura Biosciences Extends Cash Runway Into First Half 202 - Minichart
Form 8K Aura Biosciences Inc For: 11 August By Investing.com - Investing.com Nigeria
Aura Biosciences (AURA) doubles assets after $280.8M raise as losses mount - stocktitan.net
Aura Biosciences Q2 Loss Widens - marketscreener.com
Aura Biosciences Restructures, Refocuses on Ocular Oncology - TipRanks
Earnings Flash (AURA) Aura Biosciences Posts Q2 Net Loss $0.48 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Aura Biosciences, Inc. Q2 2026: Net loss $45.6M, EPS $(0.48) — 10-Q Summary - TradingView
AURA: Q2 net loss widened to $45.6M; $280.8M raised, restructuring shifts focus to ocular oncology - TradingView
Aura Biosciences Reports 45.6 Million Dollar Q2 Net Loss - Quiver Quantitative
AURA: Fully enrolled Phase 3 trial and strategic focus on ocular oncology extend cash runway to 1H 2029 - TradingView
Aura Biosciences, Inc. Announces Executive Changes - marketscreener.com
Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Layoff Tracker: Aura, Schrödinger trim workforces - BioSpace
Responsive Playbooks and the AURA Inflection - Stock Traders Daily
Aura Biosciences (NASDAQ:AURA) Raised to Hold at Wall Street Zen - marketbeat.com
Aura Biosciences Expands Authorized Shares and Incentive Plan - TipRanks
Aura Biosciences (AURA) Projected to Announce Quarterly Earnings on Wednesday - MarketBeat
AURA Q2'26 Earnings: EPS estimate is (0.38) USD - TradingView
InvestingPro Fair Value predicted Aura Biosciences’ 40% decline By Investing.com - Investing.com Nigeria
Aura Biosciences, Inc. Revenue Breakdown – NASDAQ:AURA - TradingView
AURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Understanding the Setup: (AURA) and Scalable Risk - Stock Traders Daily
Aura Biosciences Inc (AURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
AURA|Aura Biosciences Inc|Price:7.155|Chg%:+0.105 - TradingKey
BlackRock (AURA holder) discloses 4.4% Aura Biosciences stake in amended filing - Stock Titan
Aura Biosciences Inc (AURA) Institutional Confidence - TradingKey
Aura Biosciences Inc (AURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aura Biosciences Inc (AURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Gibney Anthony S | See Remarks |
Jun 16 '26 |
Sale |
6.42 |
12,824 |
82,330 |
265,354 |
| Matrix Capital Management Comp | 10% Owner |
May 07 '26 |
Sale |
5.64 |
6,922,870 |
39,044,987 |
0 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):